COVID-19 Therapeutics Market [Drug Class: Corticosteroids, Anti-viral, Monoclonal Antibodies, Kinase Inhibitors, and Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Jan 2023| TMR3574A| Transparency

Report Highlights

COVID-19 Therapeutics Market – Scope of Report

TMR’s report on the global COVID-19 therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global COVID-19 therapeutics market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global COVID-19 therapeutics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the COVID-19 therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global COVID-19 therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global COVID-19 therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global COVID-19 therapeutics market.

The report delves into the competitive landscape of the global COVID-19 therapeutics market. Key players operating in the global COVID-19 therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global COVID-19 therapeutics market profiled in this report.

RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market COVID-19 therapeutics.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

  • Company websites, presentations, annual reports, white papers, technical paper, product brochure
  • Internal and external proprietary databases and relevant patents
  • National government documents, statistical databases, and market reports
  • News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

  • Industry Sources:
    • WorldWideScience.org
    • Elsevier, Inc.
    • National Institutes of Health (NIH)
    • PubMed
    • NCBI
    • Department of Health Care Service
  • Trade Data Sources
    • Trade Map
    • UN Comtrade
    • Trade Atlas
  • Company Information
    • OneSource Business Browser
    • Hoover’s
    • Factiva
    • Bloomberg
  • Mergers & Acquisitions
    • Thomson Mergers & Acquisitions
    • MergerStat
    • Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening secondary research findings
  • Further develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

  • Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
  • Purchasing/Sourcing managers, technical personnel, distributors
  • Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
  • Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

  • Advanced Oncotherapy PLC
  • Danfysik A/S
  • Hitachi, Ltd.
  • IBA Worldwide
  • Mevion Medical Systems, Inc.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2022-2031
Growth rate -8.30%
Units considered $ Million
Segments covered By Route of Administration, By Drug Claas, By Distribution Channel, By Region
Industry covered Pharmaceutical
Countries covered North America, Latin America, Europe, Asia Pacific, Middle East & Africa
Companies studied
  • F. Hoffmann-La Roche Ltd,
  • Eli Lilly and Company,
  • Gilead Sciences, Inc.,
  • Celltrion Healthcare Co.,Ltd.,
  • Pfizer Inc.,
  • Merck & Co., Inc.,
  • GSK plc.,
  • Sorrento Therapeutics, Inc.,
  • AstraZeneca

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others

Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

  • Table 1 : Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
  • Table 2 : Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
  • Table 3 : Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
  • Table 4 : Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031
  • Table 5 : North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031
  • Table 6 : North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
  • Table 7 : North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
  • Table 8 : North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
  • Table 9 : Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
  • Table 10 : Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
  • Table 11 : Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
  • Table 12 : Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
  • Table 13 : Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
  • Table 14 : Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
  • Table 15 : Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
  • Table 16 : Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
  • Table 17 : Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
  • Table 18 : Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
  • Table 19 : Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
  • Table 20 : Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
  • Table 21 : Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
  • Table 22 : Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
  • Table 23 : Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
  • Table 24 : Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
  • Figure 1 : Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 2 : COVID-19 Therapeutics Market Value Share, by Drug Class, 2021
  • Figure 3 : COVID-19 Therapeutics Market Value Share, by Route of Administration, 2021
  • Figure 4 : COVID-19 Therapeutics Market Value Share, by Distribution Channel, 2021
  • Figure 5 : COVID-19 Therapeutics Market Value Share, by Region, 2021
  • Figure 6 : Global COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 7 : Global COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
  • Figure 8 : Global COVID-19 Therapeutics Market Value (US$ Mn), by Corticosteroids, 2017‒2031
  • Figure 9 : Global COVID-19 Therapeutics Market Value (US$ Mn), by Anti-viral, 2017‒2031
  • Figure 10 : Global COVID-19 Therapeutics Market Value (US$ Mn), by Monoclonal Antibodies, 2017‒2031
  • Figure 11 : Global COVID-19 Therapeutics Market Value (US$ Mn), by Kinase Inhibitors, 2017‒2031
  • Figure 12 : Global COVID-19 Therapeutics Market Value (US$ Mn), by Others (Anti-inflammatory Drugs, Convalescent Plasma, Others) 2017‒2031
  • Figure 13 : Global COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 14 : Global COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
  • Figure 15 : Global COVID-19 Therapeutics Market Value (US$ Mn), by Parenteral, 2017‒2031
  • Figure 16 : Global COVID-19 Therapeutics Market Value (US$ Mn), by Oral, 2017‒2031
  • Figure 17 : Global COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel 2021 and 2031
  • Figure 18 : Global COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel 2022–2031
  • Figure 19 : Global COVID-19 Therapeutics Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031
  • Figure 20 : Global COVID-19 Therapeutics Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
  • Figure 21 : Global COVID-19 Therapeutics Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031
  • Figure 22 : Global COVID-19 Therapeutics Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 23 : Global COVID-19 Therapeutics Market Attractiveness Analysis, by Region, 2022–2031
  • Figure 24 : North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 25 : North America COVID-19 Therapeutics Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 26 : North America COVID-19 Therapeutics Market Attractiveness Analysis, by Country, 2022–2031
  • Figure 27 : North America COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 28 : North America COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class 2022–2031
  • Figure 29 : North America COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 30 : North America COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration 2022–2031
  • Figure 31 : North America COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 32 : North America COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
  • Figure 33 : Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 34 : Europe COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 35 : Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
  • Figure 36 : Europe COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 37 : Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
  • Figure 38 : Europe COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 39 : Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
  • Figure 40 : Europe COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 41 : Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
  • Figure 42 : Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 43 : Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 44 : Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
  • Figure 45 : Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 46 : Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
  • Figure 47 : Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 48 : Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
  • Figure 49 : Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 50 : Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
  • Figure 51 : Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 52 : Latin America COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 53 : Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
  • Figure 54 : Latin America COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 55 : Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
  • Figure 56 : Latin America COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 57 : Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
  • Figure 58 : Latin America COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 59 : Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
  • Figure 60 : Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 61 : Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 62 : Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
  • Figure 63 : Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 64 : Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
  • Figure 65 : Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 66 : Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
  • Figure 67 : Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 68 : Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
  • Figure 69 : Company Share Analysis

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Transparency
Price: $5795

Become a Member

Already a member? Login here.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS